GleamWall
中文EN

LFCR LIFECORE BIOMEDICAL, INC. \DE\

Pharmaceutical Preparations · Nasdaq · SEC CIK 1005286 · Fiscal year ends 05/25

Financial factors as of 2025-05-25 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY0.5%
TTM net income YoY-422.3%
TTM EPS YoY-484.8%
Revenue 3-yr CAGR5.0%
Net income 3-yr CAGR—

Margins

Gross margin31.3%
Operating margin-13.4%
Net margin-30.0%
FCF margin-10.6%
EBITDA margin-7.2%

Returns

ROE-612.1%
ROA-15.7%
ROIC (approx.)-10.7%
Asset turnover0.52x

Leverage & solvency

Liabilities / assets80.2%
Debt / equity100.20x
Current ratio2.84x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.00x
Accruals ratio-15.6%
Payout ratio—
Capex / revenue10.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312026Q12025-09-302025Q42025-05-252025Q32025-02-232025Q22024-11-242025Q12024-08-25
Income statement
Revenue$25.32M$34.17M$23.19M$31.11M$36.44M$35.15M$32.56M$24.70M
Cost of revenue$18.50M$22.09M$18.73M$23.32M$22.46M$25.31M$21.48M$19.32M
Gross profit$6.83M$12.07M$4.46M$7.79M$13.98M$9.85M$11.08M$5.39M
R&D expense$1.42M$1.54M$1.22M$1.96M$2.10M$2.04M$1.92M$2.19M
SG&A expense$6.30M$7.97M$7.92M$8.89M$8.98M$9.98M$11.12M$14.79M
Operating income-$894,000$2.57M-$4.67M-$3.07M$5.33M-$9.03M-$1.96M-$11.58M
Interest expense$8.10M$7.75M$7.35M$6.38M$5.73M$5.59M—$5.38M
Pretax income-$40.03M-$6.13M-$14.94M-$9.66M-$1.11M-$14.78M-$6.53M-$16.25M
Income tax$51,000$23,000$43,000$333,000$33,000-$8,000$43,000-$25,000
Net income-$40.08M-$6.16M-$14.98M-$9.99M-$1.15M-$14.77M-$6.57M-$16.23M
EBITDA$1.52M$5.08M-$2.36M-$1.09M$7.24M-$6.95M$85,000-$9.59M
EPS (basic)-1.08-0.19-0.43-0.29-0.06-0.42-0.25-0.53
EPS (diluted)-1.08-0.19-0.43-0.29-0.06-0.42-0.25-0.53
Weighted avg. shares (diluted)37.85M37.57M37.48M37.40M37.01M37.02M34.36M30.86M
Balance sheet
Cash & equivalents$23.04M$17.24M$20.80M$18.86M$8.27M$5.42M$9.46M$5.52M
Receivables——————$30.30M$25.14M
Inventory$27.70M$25.48M$28.16M$33.80M$32.29M$34.60M$39.21M$41.64M
Current assets$84.68M$83.69M$77.64M$83.93M$85.68M$84.21M$81.86M$74.18M
PP&E, net$122.04M$123.71M$125.51M$128.57M$129.01M$128.22M$150.58M$148.76M
Goodwill$13.88M$13.88M$13.88M$13.88M$13.88M$13.88M$13.88M$13.88M
Intangibles———$4.20M$4.20M$4.20M$4.20M$4.20M
Total assets$228.30M$229.50M$225.50M$235.20M$239.34M$237.69M$255.39M$246.82M
Current liabilities$22.04M$21.64M$20.50M$29.96M$30.18M$31.12M$35.29M$40.52M
Short-term debt$978,000$970,000$962,000$947,000$3.44M$930,000$773,000$773,000
Long-term debt$160.97M$155.07M$148.74M$135.95M$130.44M$124.94M$110.53M$105.55M
Total debt$161.94M$156.04M$149.70M$136.90M$133.87M$125.87M$111.30M$106.32M
Total liabilities$250.58M$213.41M$204.72M$198.42M$191.91M$190.27M$195.63M$207.32M
Shareholders' equity-$73.40M-$34.09M-$28.44M-$10.54M$1.34M$2.22M$15.45M-$3.94M
Net debt$138.91M$138.80M$128.91M$118.04M$125.61M$120.45M$101.85M$100.80M
Shares outstanding37.91M37.70M37.48M37.47M37.03M37.03M36.98M30.90M
Cash flow statement
Operating cash flow$6.95M-$2.19M$4.70M$1.76M$5.35M$1.20M-$6.11M-$613,000
Capital expenditure$912,000$513,000$1.12M$1.74M$2.10M$5.46M$2.47M$3.42M
Free cash flow$6.03M-$2.70M$3.58M$25,000$3.25M-$4.26M-$8.58M-$4.04M
Investing cash flow-$912,000-$513,000-$1.12M-$1.74M-$2.10M$1.54M-$2.47M-$3.42M
Financing cash flow-$240,000-$852,000-$256,000-$1.39M-$402,000-$6.78M$12.52M$1.09M
Depreciation & amortization$2.41M$2.52M$2.31M$1.98M$1.91M$2.08M$2.04M$1.99M
Stock-based compensation$1.72M$2.08M$1.70M$2.39M$1.81M$2.55M$3.37M$2.42M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.